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The Oral Contraceptive as
Abortifacient: An Analysis
of the Evidence
Dennis M. Sullivan
Pro-life Christian ethicists and medical practitioners have been united in their opposition to
abortion, but have sometimes been divided in their ethical approach to hormonal contraception.
Even though many Christians believe that birth control may be a moral option, some claim that
the “Pill” acts, at least some of the time, as an abortifacient. If true, Christians who hold that
human personhood begins at conception would be morally opposed to the use of combined oral
contraceptives.
This article examines the scientific evidence for an abortifacient effect of such contraceptive
agents, and concludes that such an effect is yet unproven. Some of the ethical arguments are
also examined, and the author suggests that further research on early pregnancy factor (EPF)
may help to resolve this controversial issue.
A
s an ethical litmus test, the abortion
debate separates large segments of
secular and religious communities.
Social conservatives have opposed all forms
of abortion on absolutist grounds, allowing
only rare exceptions where the life of the
mother is truly at stake. Furthermore, the
pro-life cause has been championed by con-
servative elements within denominations,
so that conservative Roman Catholics and
conservative Protestants have found com-
mon cause. As James Nuechterlein has put
it: “Conservative Catholics and Protestants
stand together in opposition to their liberal
coreligionists.”1
A major exception to this unified voice is
the issue of contraception. The Roman Cath-
olic Church has traditionally opposed artifi-
cial birth control, mostly on the ground of
natural law, claiming that sexual union must
always allow for the possibility of procre-
ation. Protestants, less influenced by natural
law (at least in this regard), have held a more
permissive view. They have felt that the
unitive and procreative aspects of intimacy
within marriage may be separated, and thus
are open to interventions that prevent the
creation of new life.2
In all of this, one principle is clear: there
are conservative elements in both religious
traditions that agree on the sanctity of human
life from conception, and therefore oppose
abortion. Recently, some pro-life writers have
condemned hormone contraceptives as actu-
ally causing an early abortion. If this abor-
tifacient action were true, then the Catholic
and Protestant sides might join together to
condemn such contraceptive methods. Other
writers, however, have dismissed the aborti-
facient evidence as inconclusive, leading to
an unresolved debate within the pro-life
family about the morality of oral contracep-
tives. This paper will summarize the avail-
able evidence on this question, and will offer
a suggestion to help settle the issue.
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Some Background
Physiology
To better understand the issues that sur-
round oral contraceptives, some of the back-
ground of the normal uterine cycle and of
early pregnancy will be helpful. The uterus
lies within the lower abdomen, where it is
held in place by suspensory ligaments. The
normal uterus is shaped like a small bottle,
with the muscular cervix acting as the “bot-
tle neck” where menstrual flow emerges into
the vagina, and where sperm night possibly
enter the uterus during sexual intimacy. On
each upper side of the uterus are the uterine
(“Fallopian”) tubes. The uterine tubes termi-
nate in the ampulla, a wider area with many
finger-like projections that envelop the ovary
on each side. The ampulla acts to collect the
ovum after ovulation occurs.
The two ovaries produce reproductive
cells (ova) that a woman releases monthly in
the process of ovulation (note: the technical
term for a pre-ovulation reproductive cell is
secondary oocyte, but in the interest of brevity
this article will use the more general term
ovum). At puberty, the ovaries together
contain about 40,000 potential ova, of which
about four hundred will mature and be
released during a woman’s lifetime.3
The key endocrine hormones in the female
reproductive cycle are GnRH, FSH, LH,
estrogen, progesterone, relaxin, and inhibin.
Gonadotropin-releasing hormone (GnRH) is
made in an area at the base of the brain
called the hypothalamus. This hormone con-
trols release of follicle stimulating hormone
(FSH) and luteinizing hormone (LH) from
the anterior pituitary gland. Various forms
of estrogen (primarily ß-estradiol) and pro-
gesterone are both made by the ovary at
various stages of a woman’s monthly cycle.
Estrogen controls female sexual character-
istics and stimulates development of the
endometrium, the inner lining of the uterus.
Progesterone works with estrogen to stimu-
late the endometrium and prepares the
breasts to secrete milk. Both estrogen and
progesterone inhibit (through negative feed-
back) the release of GnRH and LH, and
estrogen also inhibits FSH. The ovary also
produces the hormones relaxin and inhibin.
Because the role of these last two hormones
does not directly impact this discussion,
they will not be considered further here.4
In the normal twenty-eight days of the
female uterine cycle, GnRH stimulates the
release of FSH and LH. The release of these
hormones, in turn, causes development of
ovarian follicles. The follicles are the cell-
lined spaces where the ova reside. One dom-
inant ovum tends to suppress the others,
so that it becomes larger and larger. As it
does so, it secretes more and more estrogen.
Estrogen causes development and thicken-
ing of the endometrium (this is called the
“proliferative phase” of the uterine cycle).
The estrogen exerts positive feedback on
the hypothalamus, causing an increase in
secretion of GnRH. This leads to a sudden
increase in LH (called the “LH surge”),
which initiates rupture of the follicle and
ovulation. The follicular “shell” left over
after ovulation, called the corpus luteum,
is itself a rich source of hormones. LH causes
the corpus luteum to secrete additional
estrogen and progesterone. In the last four-
teen days of the cycle (under the influence of
these hormones), the endometrium becomes
thicker, has more blood vessels, and devel-
ops secretory glands (this is the “secretory
phase” of the uterine cycle).
The secretory phase of the female cycle is
the only time that the endometrium is pre-
pared for implantation of a fertilized ovum.
If this does not occur, the corpus luteum
degenerates, depriving the endometrium of
progesterone, which leads to its collapse.
The inner layer of the endometrium sloughs,
creating the menstrual flow, and a new cycle
begins.
Fertilization of an ovum by a sperm cell
normally occurs in the uterine tube near the
ampulla. The new embryo then travels down
the uterine tube, with implantation into the
endometrium occurring about six days later,
and a new pregnancy is then well estab-
lished. What happens to the corpus luteum,
upon which survival of the inner endome-
trium depends? If implantation is successful,
the developing embryo produces a hormone
called human chorionic gonadotropin (hCG).
This hormone acts like LH to stimulate the
corpus luteum to continue its secretion of
estrogen and progesterone. This so-called
“rescue” of the corpus luteum allows it
to continue to produce progesterone, and
the endometrium is maintained, which will
eventually develop into the placenta of the
developing fetus.5
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acts as an
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at least some
of the time …
Mechanisms of Hormonal Contraception
The most common oral contraceptive pill used today is a
combination of an estrogen, usually ethinyl estradiol but
occasionally an analogue called mestranol, plus one of
eight possible synthetic progestins (progesterone-like com-
pounds): norethindrone, norethindrone acetate, ethynodiol
diacetate, norgestrel, levonorgestrel, desogestrel, gesto-
dene, and norgestimate.6 This type of pill is often called a
combined oral contraceptive (COC). First introduced in
the early 1960s, COCs formerly contained much higher
doses of both components, but this was associated with
higher risks for heart disease, stroke, and venous blood
clots. This has led to a reduction in the dose of estrogens
and progestins.7 These newer formulations have not seem-
ingly reduced contraceptive efficacy, but have increased
the concern over possible abortifacient effects.8
COCs act primarily by inhibiting the release of GnRH
from the hypothalamus. This in turn leads to a reduction
in levels of LH and FSH. As a result, follicles do not develop
in the ovary, and the mid-cycle LH surge is absent, which
removes the stimulus for follicle rupture and ovulation.
COCs also have a second mechanism: they cause thicken-
ing of the cervical mucous, adding an additional barrier
to sperm penetration should ovulation occur.9
Concern about a third mechanism of action comes from
the standard “package insert” that accompanies COCs.
Consider, for example, this Web site description from
Ortho-McNeil about their popular contraceptive product,
Ortho Tri-Cyclin Lo:
By delivering an adequate amount of progestin and
estrogen throughout your body, ORTHO TRI-
CYCLEN LO stops ovulation from occurring.
ORTHO TRI-CYCLEN LO also thickens the cervical
mucus, making it difficult for sperm to enter the
uterus, and changes the lining of the uterus to reduce
the likelihood of implantation.10
It is the last phrase in the description that creates a moral
issue for some pro-life Christians. If the presence of proges-
tins in COCs prevents the endometrium from supporting
implantation, then the “Pill” acts as an abortifacient, at least
some of the time (according to the conception view of
human personhood).
To be fair to Ortho-McNeil and other companies
involved with the manufacture of these drugs, they are
trying to reassure their potential customers that their
products work well. The key questions for contraceptive
users are: “Is it safe?” and “Will it reliably prevent preg-
nancy?” The lower doses of estrogen and progestins in
COCs make the medication relatively safe for women who
do not smoke and who do not have a history of heart
disease, abnormal clotting, or stroke. As to the second
question, the bottom line is the pregnancy rate. To this
point, there is a failure rate for contraceptive use: up to 5%
for typical users, but dropping to 0.1% for highly compli-
ant use.11 The manufacturers of oral contraceptives are
not necessarily concerned with “fine points” of ethics, so
they will understandably make somewhat biased claims
to insure a strong market for their products.
The preponderance of evidence shows that COCs work
by suppressing ovulation most of the time.12 As stated
earlier, in the rare event that “breakthrough” ovulation
occurs, (also called “escape” ovulation or “on-pill” ovula-
tion), COCs also cause thickening of the cervical mucous,
making it more difficult for sperm to enter the cervix.
Both of the above mechanisms are true contraceptive effects,
i.e., that prevent fertilization. As to the third possible effect
of COCs, this would be an interceptive effect, where the
action of progestins on the endometrium make it unrecep-
tive for implantation. Despite this theoretical possibility,
Keder has said: “There is no direct evidence that this con-
tributes to the effectiveness of oral contraceptives.”13
The Oral Contraceptive as Abortifacient:
The Scientific Debate
As proposed by physician Walter Larimore and popular
Christian writer Randy Alcorn, the case against COCs has
been dubbed the “hostile endometrium” theory. Larimore
and Stanford have presented their scientific argument in
a major medical journal14 and Alcorn eloquently expresses
these ideas for a lay readership in booklet form.15 Their
basic premises are analyzed here.
1. Women who take oral contraceptives have a thinner and less
receptive endometrium.
Women who take COCs have a thinner endometrial lining,
as well as other biochemical changes, compared with non-
Pill users. Larimore and Stanford cite a number of pharma-
cological and gynecological studies to make this point,16
and both sides of the debate seem willing to concede this.17
2. A thinner endometrium will decrease the likelihood of success-
ful implantation.
This is suggested by studies involving embryo transfer
during in-vitro fertilization (IVF). Noyes and colleagues,
for example, retrospectively studied endometrial thickness,
as determined by ultrasonography, and concluded that
a minimum thickness of 9 mm was needed for success in
achieving pregnancy.18 On the other hand, this idea was
tested prospectively in 135 patients in a university setting,
and endometrial thickness was not predictive of IVF out-
comes.19 Though the clinical evidence is inconclusive,
endometrial thickness as a determinant of successful
implantation is at least theoretically reasonable, since this
assumption affects the practice of embryo transfer in many
assisted reproduction clinics.20
3. If breakthrough ovulation occurs, the effects of contraceptives
on the endometrium make the embryo less likely to implant.
This is the highly debated issue. Those who write in sup-
port of COCs admit that the endometrium is thinner during
non-ovulatory cycles (as is typical with Pill users). For the
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purposes of argument, they may even grant
that a thinner endometrium may be less
hospitable for implantation (though this is
not completely clear). However, if ovulation
takes place, a completely different hormonal
milieu exists. As summarized earlier, ovula-
tion leaves behind the corpus luteum, a rich
source of estrogen and progesterone. After
the six days required for the embryo to travel
down the uterine tube into the uterus, these
hormones have transformed the endome-
trium, which has now become receptive for
implantation.21
There is no doubt that this is true at least
some of the time. This should be obvious
from the known “failure” rate of the Pill
cited earlier (0.1–5%). In other words, some
Pill-users get pregnant. The key questions
become: How often does the user of COCs
ovulate and conceive, only to have such a
conception fail to implant? How does this
rate compare with non-Pill users?
The baseline failure rate for implantation
is an important statistic in this regard. A full
70% of fertilized ova fail to proceed to a full-
term pregnancy, with three-fourths of these
due to failure of implantation.22 Against this
failure rate, the rarity of breakthrough ovu-
lation makes statistical comparison of Pill-
users against non-Pill users difficult. Contra-
ceptive opponents must make a difficult
statistical case: (1) In instances of break-
through ovulation (a rare event), a significant
number of sperm must penetrate the thick-
ened cervical mucous (presumably a rare
event), thus evading both truly contracep-
tive effects of COCs; and (2) If fertilization
does occur, an embryo must fail to implant
in an endometrium at least somewhat pre-
pared for it, or if it implants, fail to continue
to term, and this failure rate must be greater
than the 70% that occurs naturally.
A distinction is necessary here. This arti-
cle has focused on COCs, but other types
of contraceptives are available. In particular,
progestin-only contraceptives (POPs) are
attractive because they limit Pill-related side
effects. However, their overall efficacy is
less, and they statistically increase the likeli-
hood of ectopic (tubal) pregnancy, a danger-
ous condition that can led to rupture and
bleeding, with serious consequences for the
mother. This risk is usually expressed as the
ectopic/intrauterine pregnancy ratio (E/I
ratio).23 Progestin implants (e.g., Norplant)
offer the advantage that compliance is not
an issue. They are also more effective than
POPs in preventing ovulation.24 However,
for unclear reasons, the ectopic pregnancy
rate is also statistically higher when (rarely)
breakthrough ovulation does occur. These
considerations, according to Crockett and
colleagues, present unacceptable added
medical risks to women, making both POPs
and Norplant undesirable choices.25 In addi-
tion, the higher ectopic rate means that more
breakthrough ovulation pregnancies fail to
implant, which bolsters the ethical case that
these agents are abortifacients.
It is important to be clear on this point.
Opponents of all hormonal contraceptives
have argued that they statistically increase
the ectopic pregnancy rate (i.e., they increase
the E/I ratio in pregnancies resulting from
breakthrough ovulation). However, these
writers combined POPs and COCs together
in the data pool. If POPs were excluded
and the E/I ratio calculated for COCs alone,
there would appear to be no specific evi-
dence indicting COCs for the increase in
ectopic pregnancies.26
There is also an important distinction
between COCs and emergency contracep-
tion (EC). With EC (sometimes referred to as
the “morning-after pill”), a four-times nor-
mal dose of a combined oral contraceptive
pill is taken over a 12-hour period. Since this
regimen is designed to prevent pregnancy
after unprotected sexual intercourse, it may
act in two ways: (1) by preventing ovulation,
or (2) by interfering with implantation if
ovulation (and therefore fertilization) had
already occurred.27 Many (including the
present author) feel that the supra-physio-
logical dose of hormones used for EC is
therefore an abortifacient at least part of the
time, though others would dispute this.28
Based on this use (and many would say
abuse) of oral contraceptives, Wilks has
argued that this supports the moral case
against them.29 However, at the very least,
the standard use of COCs is not in view here.
If it is granted (as it seems reasonable to do)
that EC often acts as an abortifacient, it does
not follow that the same mechanism applies
to the lower dose used in standard contra-
ceptive formulations.
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To summarize the scientific case indicting COCs as
having an abortifacient action, the evidence appears
inconclusive at the present time. Several leading profes-
sional organizations have looked at the evidence, and have
been unable to reach a consensus. For example, the Ameri-
can Association of Pro-Life Obstetricians and Gynecolo-
gists has carefully studied this issue, and has reached the
conclusion that “our knowledge of the truth is incom-
plete.”30 The Christian Medical and Dental Association
holds a similar view: “This issue cannot be resolved with
our current understanding.”31 While not drafting a posi-
tion statement on the issue, the Center for Bioethics and
Human Dignity has presented both sides of the debate.32
All of these organizations support the right of conscience
for health care providers to not prescribe or dispense
these drugs, if such professionals are concerned about
a possible abortifacient effect.
The Oral Contraceptive as Abortifacient:
Some Ethical Comments
Though this article has focused on the scientific evidence,
a few remarks from an ethical perspective are in order.
This author holds to the conception view of human
personhood, and holds that if a true abortifacient effect
were demonstrated for COCs, then the Pill would be an
immoral intervention into the reproductive process. How-
ever, the evidence is inconclusive. How should Christian
health professionals respond?
Larimore and Stanford have cogently argued that the
possibility of a post-fertilization effect should be part of
informed consent for prescribing oral contraceptives.33
This seems reasonable where the evidence is clear, as in
the case of POPs, or where there are clearly defined other
risks, as in the statistically higher possibility of ectopic
pregnancy with Norplant. However, since the evidence
for COCs is not conclusive, it is not clear what health-care
providers should tell their patients. Sherfey has responded
in this way:
Obtaining informed consent of a general medical-
legal nature to cover the possible adverse effects and
complications of various methods of birth control
is already a common practice. Yet to also educate
interested patients specifically that there may be
postfertilization effects would be a new practice for
many physicians and health care providers.34
As an added ethical argument against contraceptive
use, Larimore has argued that the classic principle of
double effect may provide additional guidance.35 In this
principle, a contemplated action (e.g., giving morphine
to a terminally ill patient) may have both a good effect
(the relief of pain) and a bad effect (hastening death).
For an action to be moral, the good effect must be intended,
even though the bad effect may be foreseeable.36
Larimore lays out five conditions for proper applica-
tion of this principle, including the condition that there
exists no other way to produce the good effect. He rightly
argues that there is indeed an alternative to oral contra-
ception, that of natural family planning, a sophisticated
modern option that has little resemblance to the “rhythm
method” of twenty years ago. On this basis, he argues
that the rules for applying the principle of double effect
are not fulfilled, and therefore this principle cannot be an
ethical justification for oral contraceptive use.37
Yet surely Larimore commits, at least in part, the petitio
principii fallacy, where he implicitly assumes as true that
which he would prove. In the case of morphine in terminal
patients or other applications of the principle of double
effect, the contemplated intervention has known “bad”
consequences (such as the inhibition of respiratory drive
with morphine). In the case of COCs, the “bad effect” is
unknown or unclear. The principle of double effect is sim-
ply not applicable here.
The Oral Contraceptive as Abortifacient:
The Future of the Debate
Many writers on this issue would abandon COCs as a
moral option if COCs truly could be shown to be aborti-
facient. The problem has been to precisely define when
breakthrough ovulation occurs during COC use, and when
fertilization occurs. Armed with this information, the rate
of implantation can then be statistically compared with
the natural rate, and conclusions can be drawn.
Standard pregnancy tests depend upon the presence of
hCG in maternal blood, which does not rise to measurable
quantities until well after implantation. Until recently, there
has not been a maternal test that could reliably diagnose
fertilization prior to implantation. Australian researcher
Alice Cavanagh has worked extensively with a maternal
protein called early pregnancy factor (EPF), first described
in 1974 by Morton and colleagues.38 Cavanagh describes
EPF in this way:
Prevailing orthodoxy held that maternal recognition
of pregnancy did not occur until implantation; prior
to this, the embryo was thought to be merely a silent
passenger in the maternal reproductive tract. It is
now known that there is extensive cross-talk between
mother and embryo throughout the pre-implanta-
tion period. However, EPF is still one of the earliest
manifestations of this changed physiological status
of the mother, opening a unique diagnostic window
on this stage of pregnancy.39
In passing, it is worth noting that the above is an eloquent
rebuff to those who would claim that “pregnancy” begins
with implantation, a euphemistic justification for early
abortion, human embryonic stem cell research, and other
morally problematic practices.40 Cavanagh goes on to say
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that “EPF could be valuable in discriminating
between failure to fertilize and failure to
implant.”41 In other words, this is exactly the
test that will help to answer the question
posed in the oral contraceptive discussion.
What is the function of EPF? The embryo,
as an immunologically distinct foreign en-
tity, nonetheless is not rejected by the
mother’s immune system. One of the in-
triguing roles of EPF may be to suppress the
mother’s immune system, in order to allow
pregnancy to proceed.42
One of the problems with EPF is that it
exists in such minute quantities. In the past,
it has only been detectable by a complex and
indirect bioassay called the rosette inhibition
test. In recent years, this molecule has been
purified and characterized further, and ap-
pears to be similar in form to the mitochon-
drial matrix protein chaperonin 10.43 As a
therapeutic agent, this chemical messenger
may be useful for its immunosuppressive
effects, and has already been used in an ani-
mal model for this purpose.44 Nonetheless,
further research on EPF as a diagnostic tool
may ultimately help to unravel the aborti-
facient question as it relates to hormonal
contraceptives.
Conclusion
This article should not be construed as an
unqualified endorsement of hormonal meth-
ods of birth control. Indeed, there are many
methods (e.g., POPs, Norplant) that raise
serious medical and ethical questions for
pro-life health care providers. Moreover
there are reliable alternatives to hormonal
contraceptives, such as barrier methods,
natural family planning, and abstinence.
However, ethical decisions should be based
on personal convictions combined with the
best possible scientific evidence. To fail to
use a potentially useful intervention because
of minimal evidence or theoretical concerns
is not how health practitioners should live
their ethical lives.
Scripture would call on all participants in
this discussion to mutual respect and peace,
and to apply the principles of Romans 14 as
a guide to disputable matters. Though this
author would not wish to minimize the
importance of this issue, it remains a debate
“within the family.” There are other pressing
moral concerns before us, concerns about
which we will have much broader agreement.
As Christians in the health professions,
we must remain united in the defense of the
sanctity of human life, as under the author-
ity of our Sovereign Lord. 
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